Figures
- Figure 1–
Schematic of the study protocol. CXR: chest radiography; LDCT: low-dose computed tomography; QFT-GIT: QuantiFERON® TB-Gold In-Tube; TST: tuberculin skin test; AFB: acid-fast bacillus; exam: examination; LTBI: latent tuberculosis infection; HR: isoniazid/rifampicin.
- Figure 2–
Interval between tuberculosis (TB) exposure and QuantiFERON® TB-Gold In-Tube (QFT-GIT; Cellestis, Carnegie, Australia) conversion among 27 contacts without active TB. Each numbered square represents one participant and is placed at the point at which the participant started to reside with the platoon. TST: tuberculin skin test.
Tables
- Table 1– Demographic and clinical characteristics of five patients with pulmonary tuberculosis
Patient No. Age yrs Symptom duration# weeks Time from diagnosis¶ weeks AFB sputum smear Mycobacterial sputum culture RFLP pattern Radiographic findings 1 21 12 4 Positive M. tuberculosis Index case Cavitary consolidation in RUL 2 21 4 3 Negative M. tuberculosis Same as index Consolidation in RML 3 21 5 3 Negative M. tuberculosis Different from index Bronchiolitis in LLL 4 21 4 0 Negative Negative NA Bronchiolitis in RUL with pleural effusion 5 22 No symptoms 0 Negative Negative NA Bronchiolitis in RUL Patients 3 and 5 were diagnosed based on abnormal low-dose computed tomography chest lesions. AFB: acid-fast bacillus; RFLP: restriction fragment length polymorphism; M. tuberculosis: Mycobacterium tuberculosis; RUL: right upper lobe; RML: right middle lobe; LLL: left lower lobe; NA: not applicable. #: duration of respiratory symptoms before isolation; ¶: to investigation
